Previous 10 | Next 10 |
home / stock / gnftf / gnftf news
Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized b...
The following slide deck was published by Genfit SA in conjunction with this event. For further details see: Genfit (GNFT) Investor Presentation - Slideshow
Genfit SA (GNFT) Q4 2021 Earnings Conference Call April 8, 2022 8:00 a.m. ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - Chief Executive Officer Tom Baetz - Chief Financial Officer Dean Hum - Chief Scientific Officer Carol Addy - Chief Medical Office...
Genfit press release (NASDAQ:GNFT): FY GAAP EPS of €1.23. Revenue of €85.58M (+1002.8% Y/Y). Cash and cash equivalents totaled €258.8 million as of December 31, 202. Outlook 2022: Elafibranor in Primary Biliary Cholangitis, commitment for topline data reado...
The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...
GENFIT SA (GNFT) Q2 2020 Results Conference Call September 30, 2020 04:30 PM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - CEO Dean Hum - Chief Scientific Officer and COO Conference Call Participants Thomas Smith - SVB Leerink Derek Archila - Stifel...
The following slide deck was published by Genfit SA in conjunction with this Read more ...
Theratechnologies announces positive report for tesamorelin in NASH Theratechnologies Inc. ( THTX ) announced positive data corroborating the impact of tesamorelin in treating HIV-associated nonalcoholic steatohepatitis. The data has been gleaned from a sub-analysis of the Phase 2 study. T...
XBiotech makes a crucial breakthrough in True Human antibodies Development XBiotech Inc. (XBIT) reported that it has made an important breakthrough in the development of True Human antibodies, novel inflammation countering mechanism. This new type of antibody seeks to replace previous-gene...
Investment Thesis Formulating the launch plans well ahead of the approval, Intercept Pharmaceuticals, Inc. ( ICPT ) caught completely off guard when the FDA refused to sign off OCA, a Intercept’s candidate for liver fibrosis in NASH. The agency, however, hasn’t completely ...
News, Short Squeeze, Breakout and More Instantly...
Genfit Ord Company Name:
GNFTF Stock Symbol:
OTCMKTS Market:
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...